CRA-2059

• Description :

  CRA-2059 is a highly specific and selective tryptase inhibitor, with a Ki of 620 pM for recombinant human tryptase-β (rHTβ) [1][2].

• UNSPSC :

  12352005

• Target :

  Ser/Thr Protease

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/cra-2059.html

• Solubility :

  10 mM in DMSO

• Smiles :

  NC(NC1=CC=C(CNC(N2CCN(C(O[C@@H]3COC4[C@H](OC(N5CCN(C(NCC6=CC=C(NC(N)=N)C=C6)=O)CC5)=O)COC34)=O)CC2)=O)C=C1)=N

• Molecular Formula :

  C34H46N12O8

• Molecular Weight :

  750.80

• References & Citations :

  [1]Tremaine WJ, et al. Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059) : an open-label pilot study. Aliment Pharmacol Ther. 2002;16 (3) :407-413.|[2]Selwood T, et al. Potent bivalent inhibition of human tryptase-beta by a synthetic inhibitor. Biol Chem. 2003;384 (12) :1605-1611.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [256649-36-2]